• Development
    pipeline

Development Project Target Indications Modality Country Development stage
Nonclinical Phase1 Phase2/3 Filed
JPH203
(Intravenous injection)
LAT1
Biliary tract cancer
Low molecular
Japan

JPH203
(Intravenous injection)
LAT1
Biliary tract cancer
Low molecular
US

**

JPH203
(Oral administration)
LAT1
Biliary tract cancer
Low molecular
Japan and overseas

JPH203
Companion diagnostic
Non disclosure
Biliary tract cancer
Diagnostic
Japan

OKY-034
(Oral administration)
LAT1
Pancreatic cancer
Low molecular
Japan

LAT1 inhibitor
(In combination with other agents)
LAT1
Biliary tract cancer/
pancreatic cancer
Low molecular
Japan

LAT1 inhibitor
LAT1
Autoimmune disease
Low molecular
US

NKO-028/035
(PET probe diagnostic)
LAT1
Solid cancer
Diagnostic
Japan
***

table
* Ohara Pharmaceutical will file an application.
** A clinical trial is in preparation now.
*** Clinical research

COPYRIGHT ©
J PHARMA.CO.,LTD
ALL RIGHTS RESERVED